Notably, Ahr and Sirt1 have been identified recently as transcriptional activators of Fgf2137, 38, 39, an emerging metabolic regulator with potential therapeutic value for dyslipidemia, obesity, type 2 diabetes and related diseases40, 41. Here, AHR is linked to obesity due to melanocortin 4 receptor deficiency.